Screener
Indivior Pharmaceuticals, Inc. INDV Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Transaction costs related to debt refinancing | (5) | — |
| Settlement of equity awards | (21) | (3) |
| Other | 3 | — |
| Net cash provided by (used in) financing activities | 7 | (17) |
| Net (decrease) increase in cash and cash equivalents | (20) | 53 |
| Exchange differences | — | — |
| Cash and cash equivalents at beginning of period | 195 | 319 |
| Cash and cash equivalents at end of period | $175 | $372 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s cash & equivalents?
- Indivior Pharmaceuticals, Inc. (INDV) reported cash & equivalents of $175M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s cash & equivalents decreased by 53.0% year-over-year, from $372M to $175M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s cash & equivalents has grown at a -21.4% compound annual growth rate (CAGR), from $316M to $195M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Indivior Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude